Alerts will be sent to your verified email
Verify Email
NECLIFE
|
Nectar Lifesciences
|
Haleos Labs
|
Everest Organics
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
15.0 . | n/a | n/a |
|
Global DMFs filed
|
104.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
0.97 % | n/a | 1.16 % |
|
Financials
|
|||
|
5 yr Average ROE
|
-3.66 % | 9.86 % | 12.73 % |
|
5yr average Equity Multiplier
|
2.12 | 2.28 | 3.91 |
|
5yr Average Asset Turnover Ratio
|
0.73 | 0.85 | 1.13 |
|
5yr Avg Net Profit Margin
|
-2.27 % | 4.95 % | 2.92 % |
|
Price to Book
|
0.35 | 1.86 | 5.55 |
|
P/E
|
0.0 | 21.22 | 62.67 |
|
5yr Avg Cash Conversion Cycle
|
88.68 Days | -6.07 Days | -87.83 Days |
|
Inventory Days
|
136.85 Days | 78.84 Days | 61.25 Days |
|
Days Receivable
|
69.3 Days | 56.81 Days | 142.15 Days |
|
Days Payable
|
116.07 Days | 142.69 Days | 226.8 Days |
|
5yr Average Interest Coverage Ratio
|
0.46 | 4.18 | 3.02 |
|
5yr Avg ROCE
|
3.29 % | 11.01 % | 19.01 % |
|
5yr Avg Operating Profit Margin
|
5.36 % | 10.73 % | 6.68 % |
|
5 yr average Debt to Equity
|
0.71 | 0.52 | 0.84 |
|
5yr CAGR Net Profit
|
9.19 % | 8.2 % | -58.15 % |
|
5yr Average Return on Assets
|
-1.73 % | 4.32 % | 3.96 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
44.91 % | 71.41 % | 59.64 % |
|
Share Pledged by Promoters
|
98.77 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-10.89 % | 1.55 % | -14.51 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Nectar Lifesciences
|
Haleos Labs
|
Everest Organics
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|